Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Nov;26(5):615P–678P.

Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

PMCID: PMC1386642  PMID: 3207568

Full text

PDF
615P

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abul-Hajj Y. J. Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors. Cancer Res. 1982 Aug;42(8 Suppl):3373s–3377s. [PubMed] [Google Scholar]
  2. Archer C. B., MacDonald D. M. Treatment of atopic dermatitis with salbutamol. Clin Exp Dermatol. 1987 Sep;12(5):323–325. doi: 10.1111/j.1365-2230.1987.tb02500.x. [DOI] [PubMed] [Google Scholar]
  3. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beringer T. R. Salicylate intoxication in the elderly due to benorylate. Br Med J (Clin Res Ed) 1984 May 5;288(6427):1344–1345. doi: 10.1136/bmj.288.6427.1344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bevan J., Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res. 1985 Apr 15;38(2):189–194. doi: 10.1016/0049-3848(85)90060-x. [DOI] [PubMed] [Google Scholar]
  6. Bicker U., Usadel K. H. Ciamexone, a highly selective immunomodulator--a tool for autoimmune diseases? Klin Wochenschr. 1986 Dec 15;64(24):1261–1266. doi: 10.1007/BF01785706. [DOI] [PubMed] [Google Scholar]
  7. Blumer J. L., Rothstein F. C., Kaplan B. S., Yamashita T. S., Eshelman F. N., Myers C. M., Reed M. D. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr. 1985 Aug;107(2):301–306. doi: 10.1016/s0022-3476(85)80156-6. [DOI] [PubMed] [Google Scholar]
  8. Brogden R. N., Carmine A. A., Heel R. C., Speight T. M., Avery G. S. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1982 Oct;24(4):267–303. doi: 10.2165/00003495-198224040-00002. [DOI] [PubMed] [Google Scholar]
  9. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  10. Campbell F. G., Graham J. G., Zilkha K. J. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966 Jun;29(3):265–267. doi: 10.1136/jnnp.29.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I. Adverse Drug React Acute Poisoning Rev. 1986 Summer;5(2):97–136. [PubMed] [Google Scholar]
  12. Chremos A. N. Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 (Suppl 2):7–12. doi: 10.1097/00004836-198707002-00003. [DOI] [PubMed] [Google Scholar]
  13. Clarke J. G., Davies G. J., Kerwin R., Hackett D., Larkin S., Dawbarn D., Lee Y., Bloom S. R., Yacoub M., Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1987 May 9;1(8541):1057–1059. doi: 10.1016/s0140-6736(87)90483-1. [DOI] [PubMed] [Google Scholar]
  14. Coben L. A., Danziger W. L., Hughes C. P. Visual evoked potentials in mild senile dementia of Alzheimer type. Electroencephalogr Clin Neurophysiol. 1983 Feb;55(2):121–130. doi: 10.1016/0013-4694(83)90178-5. [DOI] [PubMed] [Google Scholar]
  15. Colley C. M., Fleck A., Goode A. W., Muller B. R., Myers M. A. Early time course of the acute phase protein response in man. J Clin Pathol. 1983 Feb;36(2):203–207. doi: 10.1136/jcp.36.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Collier J., Foster J. Management of a restricted drugs policy in hospital: the first five years' experience. Lancet. 1985 Feb 9;1(8424):331–333. doi: 10.1016/s0140-6736(85)91094-3. [DOI] [PubMed] [Google Scholar]
  17. Crome P., Gain R., Ghurye R., Flanagan R. J. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. Hum Toxicol. 1984 Aug;3 (Suppl):41S–48S. doi: 10.1177/096032718400300105. [DOI] [PubMed] [Google Scholar]
  18. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  19. Dessì-Fulgheri P., Bandiera F., Rubattu S., Cocco F., Madeddu P., Oppes M., Tonolo G. C., Glorioso N., Rappelli A. Comparison of sublingual and oral captopril in hypertension. Clin Exp Hypertens A. 1987;9(2-3):593–597. doi: 10.3109/10641968709164229. [DOI] [PubMed] [Google Scholar]
  20. Dikshit K., Vyden J. K., Forrester J. S., Chatterjee K., Prakash R., Swan H. J. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973 May 24;288(21):1087–1090. doi: 10.1056/NEJM197305242882102. [DOI] [PubMed] [Google Scholar]
  21. EAKINS K. E. EFFECT OF ANGIOTENSIN ON INTRAOCULAR PRESSURE. Nature. 1964 May 23;202:813–814. doi: 10.1038/202813b0. [DOI] [PubMed] [Google Scholar]
  22. Ehrly A. M. The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease. J Med. 1979;10(5):331–338. [PubMed] [Google Scholar]
  23. Evans M. A., Broe G. A., Triggs E. J., Cheung M., Creasey H., Paull P. D. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981 Oct;31(10):1288–1294. doi: 10.1212/wnl.31.10.1288. [DOI] [PubMed] [Google Scholar]
  24. Fant W. K., Ritschel W. A., Alwis S. K., Roe S., Ehret J. Prediction of steady-state nortriptyline plasma levels by the repeated one-point method. Clin Pharmacokinet. 1984 Sep-Oct;9(5):450–456. doi: 10.2165/00003088-198409050-00004. [DOI] [PubMed] [Google Scholar]
  25. Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol. 1987;26(2):73–83. doi: 10.1159/000116315. [DOI] [PubMed] [Google Scholar]
  26. Feely M., Cooke J., Price D., Singleton S., Mehta A., Bradford L., Calvert R. Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br J Clin Pharmacol. 1987 Jul;24(1):77–83. doi: 10.1111/j.1365-2125.1987.tb03139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ferner R. E., Simpson J. M., Rawlins M. D. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) 1987 May 2;294(6580):1119–1120. doi: 10.1136/bmj.294.6580.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Fogoros R. N., Anderson K. P., Winkle R. A., Swerdlow C. D., Mason J. W. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983 Jul;68(1):88–94. doi: 10.1161/01.cir.68.1.88. [DOI] [PubMed] [Google Scholar]
  29. Foster A. B., Jarman M., Leung C. S., Rowlands M. G., Taylor G. N., Plevey R. G., Sampson P. Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem. 1985 Feb;28(2):200–204. doi: 10.1021/jm00380a009. [DOI] [PubMed] [Google Scholar]
  30. Francis G. S., Siegel R. M., Goldsmith S. R., Olivari M. T., Levine T. B., Cohn J. N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985 Jul;103(1):1–6. doi: 10.7326/0003-4819-103-1-1. [DOI] [PubMed] [Google Scholar]
  31. Fuller R. W., Warren J. B., McCusker M., Dollery C. T. Effect of enalapril on the skin response to bradykinin in man. Br J Clin Pharmacol. 1987 Jan;23(1):88–90. doi: 10.1111/j.1365-2125.1987.tb03014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Gaillot J., Heusse D., Hougton G. W., Marc Aurele J., Dreyfus J. F. Pharmacokinetics and metabolism of zopiclone. Pharmacology. 1983;27 (Suppl 2):76–91. doi: 10.1159/000137914. [DOI] [PubMed] [Google Scholar]
  33. Gallagher G., Jr, Lavanchy P. G., Webster C. A., Wilson J. W., Hieble J. P., DeMarinis R. M. 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist. J Med Chem. 1985 Oct;28(10):1533–1536. doi: 10.1021/jm00148a028. [DOI] [PubMed] [Google Scholar]
  34. Gibson F. M., Mirakhur R. K., Lavery G. G., Clarke R. S. Potency of atracurium: a comparison of single dose and cumulative dose techniques. Anesthesiology. 1985 May;62(5):657–659. [PubMed] [Google Scholar]
  35. Graves P. E., Salhanick H. A. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology. 1979 Jul;105(1):52–57. doi: 10.1210/endo-105-1-52. [DOI] [PubMed] [Google Scholar]
  36. Griffiths A. N., Marshall R. W., Richens A. Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol. 1984;18 (Suppl 1):73S–82S. doi: 10.1111/j.1365-2125.1984.tb02584.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hauger-Klevene J. H. Comparison of sublingual captopril and nifedipine. Lancet. 1986 Jan 25;1(8474):219–219. doi: 10.1016/s0140-6736(86)90699-9. [DOI] [PubMed] [Google Scholar]
  38. Hay D. W., Muccitelli R. M., Tucker S. S., Vickery-Clark L. M., Wilson K. A., Gleason J. G., Hall R. F., Wasserman M. A., Torphy T. J. Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther. 1987 Nov;243(2):474–481. [PubMed] [Google Scholar]
  39. Henderson A. S., Huppert F. A. The problem of mild dementia. Psychol Med. 1984 Feb;14(1):5–11. doi: 10.1017/s0033291700003020. [DOI] [PubMed] [Google Scholar]
  40. Henry D. A., Sharpe G., Chaplain S., Cartwright S., Kitchingman G., Bell G. D., Langman M. J. The [14C]-aminopyrine breath test. A comparison of different forms of analysis. Br J Clin Pharmacol. 1979 Dec;8(6):539–545. doi: 10.1111/j.1365-2125.1979.tb01041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Igić R., Kojović V. Angiotensin I converting enzyme (kininase II) in ocular tissues. Exp Eye Res. 1980 Mar;30(3):299–303. doi: 10.1016/0014-4835(80)90010-x. [DOI] [PubMed] [Google Scholar]
  42. Jenner W. N., Martin L. E., Willoughby B. A., Fellows I. The development of a radioimmunoassay for ranitidine in biological fluids. Life Sci. 1981 Mar 23;28(12):1323–1329. doi: 10.1016/0024-3205(81)90404-5. [DOI] [PubMed] [Google Scholar]
  43. Kaufman P. L., Bárány E. H. Adrenergic drug effects on aqueous outflow facility following ciliary muscle retrodisplacement in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1981 May;20(5):644–651. [PubMed] [Google Scholar]
  44. Kirch W., Hoensch H., Janisch H. D. Interactions and non-interactions with ranitidine. Clin Pharmacokinet. 1984 Nov-Dec;9(6):493–510. doi: 10.2165/00003088-198409060-00002. [DOI] [PubMed] [Google Scholar]
  45. Kirch W., Hutt H. J., Dylewicz P., Gräf K. J., Ohnhaus E. E. Dose-dependence of the nifedipine-digoxin interaction? Clin Pharmacol Ther. 1986 Jan;39(1):35–39. doi: 10.1038/clpt.1986.6. [DOI] [PubMed] [Google Scholar]
  46. Kirch W., Logemann C., Heidemann H., Santos S. R., Ohnhaus E. E. Effect of two different doses of nitrendipine on steady-state plasma digoxin level and systolic time intervals. Eur J Clin Pharmacol. 1986;31(4):391–395. doi: 10.1007/BF00613512. [DOI] [PubMed] [Google Scholar]
  47. Kirch W., Stenzel J., Dylewicz P., Hutt H. J., Santos S. R., Ohnhaus E. E. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin. Br J Clin Pharmacol. 1986 Aug;22(2):155–159. doi: 10.1111/j.1365-2125.1986.tb05243.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Kirwan J. R., Chaput de Saintonge D. M., Joyce C. R., Currey H. L. Clinical judgment in rheumatoid arthritis. II. Judging 'current disease activity' in clinical practice. Ann Rheum Dis. 1983 Dec;42(6):648–651. doi: 10.1136/ard.42.6.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Kleinbloesem C. H., van Brummelen P., Hillers J., Moolenaar A. J., Breimer D. D. Interaction between digoxin and nifedipine at steady state in patients with atrial fibrillation. Ther Drug Monit. 1985;7(4):372–376. doi: 10.1097/00007691-198512000-00002. [DOI] [PubMed] [Google Scholar]
  50. Kline N. S., Mason B. T., Winick L. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent. Curr Ther Res Clin Exp. 1974 Aug;16(8):838–843. [PubMed] [Google Scholar]
  51. Le Bris T., Brode E. Capillary gas chromatographic determination of biperiden in human plasma. Arzneimittelforschung. 1985;35(1):149–151. [PubMed] [Google Scholar]
  52. Lennard M. S., Tucker G. T., Silas J. H., Woods H. F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica. 1986 May;16(5):435–447. doi: 10.3109/00498258609050250. [DOI] [PubMed] [Google Scholar]
  53. MACRI F. J. THE ACTION OF ANGIOTENSIN ON INTRAOCULAR PRESSURE. Arch Ophthalmol. 1965 Apr;73:528–539. doi: 10.1001/archopht.1965.00970030530016. [DOI] [PubMed] [Google Scholar]
  54. Maridonneau-Parini I., Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol. 1985 Aug;20(2):148–151. doi: 10.1111/j.1365-2125.1985.tb05047.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Mason J. W. Amiodarone. N Engl J Med. 1987 Feb 19;316(8):455–466. doi: 10.1056/NEJM198702193160807. [DOI] [PubMed] [Google Scholar]
  56. Maurer G., Loosli H. R., Schreier E., Keller B. Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos. 1984 Jan-Feb;12(1):120–126. [PubMed] [Google Scholar]
  57. McDevitt D. G., Nelson J. K. Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol. 1978 Sep;6(3):233–237. doi: 10.1111/j.1365-2125.1978.tb04590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. McGovern B., Garan H., Kelly E., Ruskin J. N. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983 Jul 16;287(6386):175–180. doi: 10.1136/bmj.287.6386.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  60. McMurray J. J., Struthers A. D. Captopril in patients with ileus. Lancet. 1988 Feb 27;1(8583):471–471. doi: 10.1016/s0140-6736(88)91260-3. [DOI] [PubMed] [Google Scholar]
  61. Mikhailidis D. P., Jeremy J. Y., Barradas M. A., Green N., Dandona P. Effect of ethanol on vascular prostacyclin (prostaglandin I2) synthesis, platelet aggregation, and platelet thromboxane release. Br Med J (Clin Res Ed) 1983 Nov 19;287(6404):1495–1498. doi: 10.1136/bmj.287.6404.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Miller W. R., Forrest A. P., Hamilton T. Steroid metabolism by human breast and rat mammary carcinomata. Steroids. 1974 Mar;23(3):379–395. doi: 10.1016/0039-128x(74)90089-0. [DOI] [PubMed] [Google Scholar]
  63. Miller W. R., Forrest A. P. Oestradiol synthesis from C19 steroids by human breast cancers. Br J Cancer. 1976 Jan;33(1):116–118. doi: 10.1038/bjc.1976.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  66. Orwin A., Wright C. E., Harding G. F., Rowan D. C., Rolfe E. B. Serial visual evoked potential recordings in Alzheimer's disease. Br Med J (Clin Res Ed) 1986 Jul 5;293(6538):9–10. doi: 10.1136/bmj.293.6538.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Pettibone D. J., Clineschmidt B. V., Lotti V. J., Baldwin J. J., Huff J. R., Randall W. C., Vacca J., Young S. D. Pharmacological profile of a new potent and specific alpha 2-adrenoceptor antagonist, L-657,743. Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):169–175. doi: 10.1007/BF00165801. [DOI] [PubMed] [Google Scholar]
  68. Piafsky K. M. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980 May-Jun;5(3):246–262. doi: 10.2165/00003088-198005030-00004. [DOI] [PubMed] [Google Scholar]
  69. Polc P., Bonetti E. P., Pieri L., Cumin R., Angioi R. M., Möhler H., Haefely W. E. Caffeine antagonizes several central effects of diazepam. Life Sci. 1981 May 18;28(20):2265–2275. doi: 10.1016/0024-3205(81)90579-8. [DOI] [PubMed] [Google Scholar]
  70. Price D. E., Mehta A., Park B. K., Hay A., Feely M. P. The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol. 1986 Dec;22(6):744–747. doi: 10.1111/j.1365-2125.1986.tb02970.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Quesniaux V., Tees R., Schreier M. H., Maurer G., van Regenmortel M. H. Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine. Clin Chem. 1987 Jan;33(1):32–37. [PubMed] [Google Scholar]
  72. Ridout S., Waters W. E., George C. F. Knowledge of and attitudes to medicines in the Southampton community. Br J Clin Pharmacol. 1986 Jun;21(6):701–712. doi: 10.1111/j.1365-2125.1986.tb05236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Rudorfer M. V., Lane E. A., Chang W. H., Zhang M. D., Potter W. Z. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol. 1984 Apr;17(4):433–440. doi: 10.1111/j.1365-2125.1984.tb02368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Ruiz-Cabello F., Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther. 1984 Nov;36(5):691–695. doi: 10.1038/clpt.1984.241. [DOI] [PubMed] [Google Scholar]
  75. Somogyi A., Gugler R. Cimetidine excretion into breast milk. Br J Clin Pharmacol. 1979 Jun;7(6):627–629. doi: 10.1111/j.1365-2125.1979.tb04655.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Spielberg S. P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc. 1984 May 15;43(8):2308–2313. [PubMed] [Google Scholar]
  77. Taylor J. C., Brauer S., Espir M. L. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981 Jan;57(663):16–18. doi: 10.1136/pgmj.57.663.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Tomson T., Tybring G., Bertilsson L., Ekbom K., Rane A. Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch Neurol. 1980 Nov;37(11):699–703. doi: 10.1001/archneur.1980.00500600047009. [DOI] [PubMed] [Google Scholar]
  79. Tschollar W., Belz G. G. Sublingual captopril in hypertensive crisis. Lancet. 1985 Jul 6;2(8445):34–35. doi: 10.1016/s0140-6736(85)90073-x. [DOI] [PubMed] [Google Scholar]
  80. Uski T. K., Andersson K. E., Brandt L., Ljunggren B. Characterization of the prostanoid receptors and of the contractile effects of prostaglandin F2 alpha in human pial arteries. Acta Physiol Scand. 1984 Aug;121(4):369–378. doi: 10.1111/j.1748-1716.1984.tb07468.x. [DOI] [PubMed] [Google Scholar]
  81. Verma S. P., Silke B., Reynolds G., Muller P., Frais M. A., Taylor S. H. Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure. Br J Clin Pharmacol. 1987 Jul;24(1):21–32. doi: 10.1111/j.1365-2125.1987.tb03131.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Vincek W. C., Constanzer M. L., Hessey G. A., 2nd, Bayne W. F. Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine. J Chromatogr. 1985 Mar 22;338(2):438–443. doi: 10.1016/0378-4347(85)80118-3. [DOI] [PubMed] [Google Scholar]
  83. Visser S. L., Van Tilburg W., Hooijer C., Jonker C., De Rijke W. Visual evoked potentials (VEPs) in senile dementia (Alzheimer type) and in non-organic behavioural disorders in the elderly; comparison with EEG parameters. Electroencephalogr Clin Neurophysiol. 1985 Feb;60(2):115–121. doi: 10.1016/0013-4694(85)90017-3. [DOI] [PubMed] [Google Scholar]
  84. Vita J. B., Anderson J. A., Hulem C. D., Leopold I. H. Angiotensin-converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci. 1981 Feb;20(2):255–257. [PubMed] [Google Scholar]
  85. WHITNEY R. J. The measurement of volume changes in human limbs. J Physiol. 1953 Jul;121(1):1–27. doi: 10.1113/jphysiol.1953.sp004926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Walley T. J., Heagerty A. M., Woods K. L., Bing R. F., Pohl J. E., Barnett D. B. Nifedipine infusion in acute myocardial infarction: experience in twelve patients. Clin Cardiol. 1987 Dec;10(12):800–803. doi: 10.1002/clc.4960101205. [DOI] [PubMed] [Google Scholar]
  87. Ward D., Kalir A., Trevor A., Adams J., Baillie T., Castagnoli N., Jr Metabolic formation of iminium species: metabolism of phencyclidine. J Med Chem. 1982 May;25(5):491–492. doi: 10.1021/jm00347a002. [DOI] [PubMed] [Google Scholar]
  88. Ward P. E., Stewart T. A., Hammon K. J., Reynolds R. C., Igic R. P. Angiotensin I converting enzyme (kininase II) in isolated retinal microvessels. Life Sci. 1979 Apr 9;24(15):1419–1423. doi: 10.1016/0024-3205(79)90013-4. [DOI] [PubMed] [Google Scholar]
  89. Weller R. A., Preskorn S. H. Psychotropic drugs and alcohol: pharmacokinetic and pharmacodynamic interactions. Psychosomatics. 1984 Apr;25(4):301-3, 305-6, 309. doi: 10.1016/S0033-3182(84)73047-7. [DOI] [PubMed] [Google Scholar]
  90. Wharton J., Gulbenkian S. Peptides in the mammalian cardiovascular system. Experientia. 1987 Jul 15;43(7):821–832. doi: 10.1007/BF01945360. [DOI] [PubMed] [Google Scholar]
  91. Wijnands W. J., Vree T. B., van Herwaarden C. L. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986 Dec;22(6):677–683. doi: 10.1111/j.1365-2125.1986.tb02957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Zeegen R., Drinkwater J. E., Dawson A. M. Method for measuring cerebral dysfunction in patients with liver disease. Br Med J. 1970 Jun 13;2(5710):633–636. doi: 10.1136/bmj.2.5710.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Zeneroli M. L., Pinelli G., Gollini G., Penne A., Messori E., Zani G., Ventura E. Visual evoked potential: a diagnostic tool for the assessment of hepatic encephalopathy. Gut. 1984 Mar;25(3):291–299. doi: 10.1136/gut.25.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Ziacchi V., Rossi A., Lomanto B. Modificazioni emodinamiche indotte dalla bumetanide endovenosa nello scompenso congestizio. G Ital Cardiol. 1981;11(1):104–109. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES